STATISTICAL INVESTIGATION ON MOST PREFFERED ANTI-MALARIA DRUGS

Abstract

This study was aimed at ascertaining the most preferred drugs in treating malaria fever in Delta State. A field survey was carried with 200 questionnaires distributed to health professionals at some selected hospitals. The data obtained were analyzed using percentages, bar chart and hypothesis testing via ANOVA and Chi-square. The result indicated that at 0.05 level of significance, some anti-malaria drugs are more preferred than others and Sulphadoxine/Pyrimethamine (SP) combinations such as Amalar, Fansidar, Maloxine, and Ritadar drugs, and next Artesunate single (dose drugs), followed by Artemissin combination therapy (ACT) (such as coartem, cotexcin) are the most preferred anti-malaria drugs in Delta State. The result shows that the perception of preferred anti-malaria drugs is independent of the status of health professionals.

 

 

 

TABLE OF CONTENTS

Title page   -        -        -        -        -        -        -        -        -        -        i                                                                                   

Certification         -        -        -        -        -        -        -        -        -        -        ii

Dedication  -        -        -        -        -        -        -        -        -        -        iii

Acknowledgement         -        -        -        -        -        -        -        -        -        iv

Abstract     -        -        -        -        -        -        -        -        -        -        v

Table of content   -        -        -        -        -        -        -        -        -        vi

                                                          CHAPTER ONE

1.1.         Introduction/Background of study  -        -        -        -        -        1                

1.2.         Statement of problem   -        -        -        -        -        -        -        5                                                  

1.3.         Objectives of the study -        -        -        -        -        -        -        5

1.4.         Research question         -        -        -        -        -        -        -        -        6

1.5.         Research hypothesis     -        -        -        -        -        -        -        6                           

1.6.         Significance of the study        -        -        -        -        -        -        -        6                        

1.7.         Scope of the study        -        -        -        -        -        -        -        -        7                                                          

1.8.         Limitation of the study -        -        -        -        -        -        -        7

1.9.         Definition of terms        -        -        -        -        -        -        -        -        7                           

CHAPTER TWO

2.0 Literature review     -        -        -        -        -        -        -        -        8                                                           

CHAPTER THREE

3.1    Population of study      -        -        -        -        -        -        -        20

3.2. Sample and Sampling techniques       -        -        -        -        -        -        20

3.3. Source and Method of data used        -        -        -        -        -        -        20

3.4.0Method of data Analysis         -        -        -        -        -        -        -        21

CHAPTER FOUR

4.1. Data Presentation  -        -        -        -        -        -        -        -        23

4.2. Data Analysis        -        -        -        -        -        -        -        -        -        25

CHAPTER FIVE

5.1. Summary      -        -        -        -        -        -        -        -        -        31

5.2. Conclusion   -        -        -        -        -        -        -        -        -        31

5.3. Recommendation   -        -        -        -        -        -        -        -        32

 Reference   -        -        -        -        -        -        -        -        -        -        33